Core Viewpoint - Weikang Pharmaceutical (300878.SZ) announced the initiation of a Phase III clinical trial to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis [1] Group 1: Clinical Trial Details - The clinical trial is a randomized, double-blind, multi-center, placebo-controlled study [1] - The trial is focused on patients with liver fibrosis due to chronic hepatitis B, specifically those with liver qi deficiency and blood stasis syndrome [1] - The project is led by Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, along with 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing Medical University First Affiliated Hospital [1]
维康药业(300878.SZ)：黄甲软肝颗粒启动临床三期试验